CME: Biliary Tract Carcinoma: Are We at the Point of Change?

Biliary Tract Carcinoma: Are We at the Point of Change?

Biliary Tract Carcinoma: Are We at the Point of Change?

Here’s how emerging treatment options are offering a brighter future for our patients with biliary tract carcinoma.

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    From a lack of treatment options to frequent relapses after surgery, biliary tract carcinoma is challenging to treat. However, there are treatment options on the horizon that can potentially change the treatment landscape, as world-renowned thought leader Dr. Do-Youn Oh explains.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Omid Hamid, MD
    Chief, Translational Research & Immunotherapy
    Director, Cutaneous Oncology
    The Angeles Clinic & Research Institute
    Los Angeles, CA

    Dr. Hamid has disclosed he receives consulting fees from Amgen, Bristol-Myers Squibb, Merck, Novartis, and Roche; and is a member of the speaker bureau for Amgen, Array, Bristol-Myers Squibb, Genentech, Novartis, and Sanofi/Regeneron.

    He does contracted research for Amgen, Arcus, Astellas, Astra Zeneca, Bristol-Myers Squibb, Celldex, CytomX, Genentech, GSK, Immunocore, Incyte, Iovance, Merck, Merck Serono, MedImmune, NextCure, Novartis, Parker Institute, Pfizer, Polynoma, Regeneron, and Roche.


    Do-Youn Oh, MD, PhD
    Division of Medical Oncology, Department of Internal Medicine,
    Seoul National University Hospital
    Cancer Research Institute, Seoul National University College of Medicine
    Seoul, Korea

    Dr. Oh has disclosed she receives consulting fees from AstraZeneca, Bayer, Halozyme Therapeutics, Inc., Merck Serono, Zymeworks and does contrated research for AstraZeneca.

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • John Pirovitz has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Review emerging molecular and immunotherapeutic approaches to BTC.
    • Analyze early phase clinical data for M7824 in patients with BTC.
  • Target Audience

    This activity is designed to meet the educational needs of practicing Oncologists and Hematologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Provider(s)/Educational Partner(s)

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free